



## RKIP: A Pivotal Gene Product in the Pathogenesis of Cancer

Guest Editor:

**Prof. Dr. Benjamin Bonavida**

Department of Microbiology,  
Immunology & Molecular  
Genetics, David Geffen School of  
Medicine at UCLA, Jonsson  
Comprehensive Cancer Center,  
University of California at Los  
Angeles, Los Angeles, CA 90095,  
USA

Deadline for manuscript  
submissions:

**closed (30 October 2021)**

### Message from the Guest Editor

Dear Colleagues,

The scope of this Special Issue is to present up-to-date reviews and original research articles on the fast-moving field regarding the pivotal role of Raf kinase inhibitor protein (RKIP) in many vital cellular processes and disease manifestations. RKIP has been reported as a tumor suppressor, an immune enhancer, a prognostic/diagnostic biomarker, and a therapeutic target. The Special Issue will include different themes on RKIP, such as the general properties of RKIP in human malignancies, its regulation by phosphorylation and micro-RNAs, signaling cross-talks, gene products regulated by RKIP or gene products that regulate RKIP expression in various cancers, the pleiotropic activities of RKIP in cancer, response to photo-oxidative damage, the role in hypoxia and cellular stress, cellular plasticity of RKIP, the role in inflammation, the role of RKIP as a prognostic/diagnostic marker, new agents as therapeutic targets directed against RKIP, used alone or in combination, in the treatment of resistant cancers to conventional therapies, etc. Manuscripts that discuss future directions and future perspectives are also welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)